Fatty liver disease in people with an underactive thyroid who do not have diabetes
Looks at how common fatty liver disease is in adults with underactive thyroid.
Plain-language title generated from the registry record
Registry title: Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease in Non-Diabetic Patients
Key facts
- Where
- Sohag, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary hypothyroidism, or with thyroid antibodies, who do not have diabetes. It checks them for fatty liver disease (MASLD).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Primary hypothyroidism (overt or sub-clinical) diagnosed within 3 months, or positive thyroid antibodies whatever the thyroid status. Liver fat is checked by ultrasound and Fibro-scan.
- Earlier treatment
- Levothyroxine treatment is allowed but not required. Cannot join if taking drugs that cause or change liver fat, or if on weight-loss treatment, unless stopped at least 3 months before screening.
- Biomarker or test result
- Positive TPO antibody or positive Thyroglobin antibody (for the antibody group)
Main reasons for not taking part
- Diabetes
- Heavy alcohol use (over 30 gm/day in men, over 20 gm/day in women)
- BMI over 40 kg/m2
- Other liver disease, such as hepatitis B or C, cirrhosis or liver cancer
- Pregnancy or active cancer
Read by machine on 12 November 2026.
Where in Egypt
- Sohag UniversitySohag, EgyptContact: Islam K Fathy, MScTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sohag University
- Trial code
- NCT07603817
- Record updated
- 2 June 2026
- Original description
This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in Hashimoto-thyroiditis vs Euthyroid controls in non-diabetic patients.Read full original descriptionShow less
Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease (MASLD) in Non-Diabetic Patients
This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in Hashimoto-thyroiditis vs Euthyroid controls in non-diabetic patients.
Inclusion: Patients aged ≥18years old who will be:; Diagnosed with primary hypothyroidism (overt or sub clinical hypothyroidism) within 3 months with or without levothyroxine treatment; Patients with positive antibody (positive TPO antibody or positive Thyroglobin antibody) irrespective of thyroid status; Metabolic dysfunction-associated steatotic liver disease (MASLD) assessment by ultrasound and Fibro-scan.
Exclusion: Patients use of drugs known to cause hepatic steatosis (e.g., amiodarone, valproate, tamoxifen, methotrexate, steroids); History of bariatric surgery or ongoing weight-loss diet (hypocaloric diet) or use of weight-loss agents unless the diet or treatment has been stopped at least 3 months before screening and that the patient has had a stable body weight (+/- 3 kg) during the 3 months before screening; Diabetic patients according to American Diabetes Association (ADA) Criteria; Other causes of chronic hepatic steatosis [e.g., positive hepatitis B virus (HBV), positive hepatitis C virus (HCV)), autoimmune disease, Wilson disease, drugs]; Presence of any systemic disease that commonly cause liver disease; Patients with active malignancy; Treatment with drugs that influence liver fat, as thiazolidinediones, α-glucosidase inhibitors, sodium-glucose -transporter 2 (SGLT2) inhibitors or any glucagon-like peptide-1 receptor agonists during the previous 3 months; Severe hepatic injury and/or significant abnormal liver function defined as aspartate aminotransferase >5× upper limit of normal (ULN) and/or alanine aminotransferase >5× ULN or elevated total bilirubin > 2 mg/dl; Excessive Alcohol consumption (> 30 gm/ day in men, 20 gm /day in women; Body mass index (BMI) index >40 kg/m2; Detection of biliary duct obstruction based on imaging studies; Evidence of cirrhosis [on basis of ultrasonography and magnetic resonance imaging (MRI )] or hepatocellular carcinoma [evidence on triphasic Computed Tomography (CT) or MRI]; Pregnant women.